Related references
Note: Only part of the references are listed.Experience of compassionate-use pegcetacoplan for paroxysmal nocturnal hemoglobinuria
Morag Griffin et al.
BLOOD (2023)
Pegcetacoplan for refractory paroxysmal nocturnal haemoglobinuria associated with the C5 genetic variant
Shinobu Tamura et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria
Raymond S. M. Wong et al.
ANNALS OF HEMATOLOGY (2022)
Somatic mutations and clonal expansions in paroxysmal nocturnal hemoglobinuria
Kohei Hosokawa et al.
SEMINARS IN HEMATOLOGY (2022)
Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria
Raymond S. M. Wong
THERAPEUTIC ADVANCES IN HEMATOLOGY (2022)
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Peter Hillmen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison
Rachel H. Bhak et al.
CURRENT MEDICAL RESEARCH AND OPINION (2021)
C3inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab
Carlos de Castro et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Use of Laser Assisted Optical Rotational Cell Analyzer (LoRRca MaxSis) in the Diagnosis of RBC Membrane Disorders, Enzyme Defects, and Congenital Dyserythropoietic Anemias: A Monocentric Study on 202 Patients
Anna Zaninoni et al.
FRONTIERS IN PHYSIOLOGY (2018)
Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention
Dimitrios C. Mastellos et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2015)